Skip to main content

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Frontiers of Medicine in China volume 4, pages 457–462 (2010)Cite this article

Abstract

This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1st, 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval = 1.10–1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval = 0.411–5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (Finland)

References

  1. Blechacz B, Gores G J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 2008, 48(1): 308–321

    Article  CAS  PubMed  Google Scholar 

  2. Welzel TM, McGlynn K A, Hsing AW, O’Brien T R, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 2006, 98(12): 873–875

    Article  PubMed  Google Scholar 

  3. Forsmo HM, Horn A, Viste A, Hoem D, èvrebø K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 2008, 7(4): 412–417

    PubMed  Google Scholar 

  4. Heimbach J K, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B, Gores G J. Transplantation for hilar cholangiocarcinoma. Liver Transpl, 2004, 10(10 Suppl 2): S65–S68

    Article  PubMed  Google Scholar 

  5. Heimbach J K, Gores G J, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis, 2004, 24(2): 201–207

    Article  PubMed  Google Scholar 

  6. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg, 2001, 88(7): 969–974

    Article  CAS  PubMed  Google Scholar 

  7. DeOliveira M L, Cunningham S C, Cameron J L, Kamangar F, Winter J M, Lillemoe K D, Choti M A, Yeo C J, Schulick R D. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg, 2007, 245(5): 755–762

    Article  PubMed  Google Scholar 

  8. Su C H, Tsay S H, Wu C C, Shyr YM, King K L, Lee C H, Lui WY, Liu T J, P’eng F K. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg, 1996, 223(4): 384–394

    Article  CAS  PubMed  Google Scholar 

  9. Stroup D F, Berlin J A, Morton S C, Olkin I, Williamson G D, Rennie D, Moher D, Becker B J, Sipe T A, Thacker S B. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008–2012

    Article  CAS  PubMed  Google Scholar 

  10. Yusuf S, Peto R, Lewis J A, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 1985, 27(5): 335–371

    Article  CAS  PubMed  Google Scholar 

  11. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer, 2002, 94(2): 428–434

    Article  CAS  PubMed  Google Scholar 

  12. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg, 2006, 13(6): 537–542

    Article  PubMed  Google Scholar 

  13. Yi B, Zhang B H, Zhang Y J, Jiang X Q, Zhang B H, Yu W L, Chen Q B, Wu M C. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 2004, 3(3): 453–457

    PubMed  Google Scholar 

  14. Huang J L, Biehl T R, Lee F T, Zimmer PW, Ryan J A Jr. Outcomes after resection of cholangiocellular carcinoma. Am J Surg, 2004, 187(5): 612–617

    Article  PubMed  Google Scholar 

  15. Fernández-Ruiz M, Guerra-Vales J M, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(42): 5279–5286

    Article  PubMed  Google Scholar 

  16. Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Elebidy E, Abdalla T, Elshobary M, Mostafa M, Foad A, Kandeel T, Abdel Raouf A, Salah T, Abu Zeid M, Abu Elenein A, Gad Elhak N, ElFiky A, Ezzat F. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology, 2006, 53(67): 5–10

    CAS  PubMed  Google Scholar 

  17. Kim H J, Yun S S, Jung K H, Kwun W H, Choi J H. Intrahepatic cholangiocarcinoma in Korea. J Hepatobiliary Pancreat Surg, 1999, 6(2): 142–148

    Article  CAS  PubMed  Google Scholar 

  18. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg, 2002, 89(12): 1525–1531

    Article  CAS  PubMed  Google Scholar 

  19. Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, Soeda J, Ogawa S. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol, 2006, 41(9): 893–900

    Article  CAS  PubMed  Google Scholar 

  20. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol, 2008, 15(2): 583–589

    Article  PubMed  Google Scholar 

  21. Zhou L, He X D, Cui Q C, Zhou WX, Qu Q, Zhou R L, Rui J A, Yu J C. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett, 2008, 264(2): 209–217

    Article  CAS  PubMed  Google Scholar 

  22. Shen W F, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui C J, Yang J M. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(47): 5976–5982

    Article  CAS  PubMed  Google Scholar 

  23. Jiang W, Zeng Z C, Tang Z Y, Fan J, Zhou J, Zeng M S, Zhang J Y, Chen Y X, Tan Y S. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol, 2010, 136(9): 1323–1331

    Article  PubMed  Google Scholar 

  24. Cho S Y, Park S J, Kim S H, Han S S, Kim Y K, Lee KW, Lee S A, Hong E K, Lee W J, Woo S M. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol, 2010, 17(7): 1823–1830

    Article  PubMed  Google Scholar 

  25. Saxena A, Chua T C, Sarkar A, Chu F, Morris D L. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg, 2010, 14(7): 1128–1138

    Article  PubMed  Google Scholar 

  26. Kannagi R. Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J, 2007, 30(3): 189–209

    PubMed  Google Scholar 

  27. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res, 1993, 53(2): 354–361

    CAS  PubMed  Google Scholar 

  28. Briggs C D, Neal C P, Mann C D, Steward W P, Manson M M, Berry D P. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer, 2009, 45(1): 33–47

    Article  CAS  PubMed  Google Scholar 

  29. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert A P, Haller A, Lafitte J J, Sculier J P. Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol, 2006, 17(11): 1673–1676

    Article  CAS  PubMed  Google Scholar 

  30. Schoenleber S J, Kurtz DM, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 2009, 100(9): 1385–1392

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Shang-Long Liu, Zi-Fang Song, Qing-Gang Hu, Shao-Bo Hu, Jun Li & Qi-Chang Zheng

  2. National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 100050, China

    Duo Shan

Authors
  1. Shang-Long Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zi-Fang Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing-Gang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Duo Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shao-Bo Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qi-Chang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qi-Chang Zheng.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Liu, SL., Song, ZF., Hu, QG. et al. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis. Front. Med. China 4, 457–462 (2010). https://doi.org/10.1007/s11684-010-0240-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-010-0240-1

Keywords

  • cholangiocarcinoma
  • prognostic factors
  • serum carbohydrate antigen 19-9